Roberto Pazo-Cid

Also affiliated with Universidad de Zaragoza, Hospital Universitario Miguel Servet, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón, Instituto Aragonés de Ciencias de la Salud

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial”.

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)01366-1

N/A

5.4DataRank · unranked

454 citations

Davide Melisi, Teresa Macarulla, Roberto Pazo-Cid, Sreenivasa R Chandana, Christelle de la Fouchardière +14 more